March 2026 in “Journal of Personalized Medicine” In this study involving South African breast cancer patients, researchers identified certain genetic variations in cytochrome P450 and other enzymes potentially linked to differences in tamoxifen treatment outcomes, suggesting a need for more comprehensive pharmacogenomic studies to optimize therapy in African populations.
13 citations
,
November 2014 in “Toxicology Letters” This study found that finasteride selectively inhibited UGT1A4 in vitro but is unlikely to cause clinically significant drug interactions mediated through hepatic UGT enzymes in vivo.
1 citations
,
September 2025 in “The Oncologist” This review discusses the management of adverse events associated with sacituzumab govitecan use in real-world settings and provides no new clinical results; it emphasizes practical strategies for clinicians treating breast cancer patients.
June 2023 in “International Journal of Pharmaceuticals Nutraceuticals and Cosmetic Science” This review compiles recent findings on the pharmacokinetics, pharmacodynamics, and pharmacogenomics of Valproate, highlighting potential new uses, benefits, and risks, but reports no new clinical results.
3 citations
,
April 2021 in “Oncology Times” This study reports that sacituzumab govitecan achieved a 33.3% overall response rate in patients with metastatic triple-negative breast cancer who had prior treatments, with a median response duration of 7.7 months.